Principal Engineer 2

ICON shares jump 13% as clinical research firm beats estimates on strong bookings and expands buyback plan. The contract research organisation reported $3.15 billion in net business wins, raised its buyback authorisation and forecast 2026 revenue of up to $8.2 billion. Published 10/29/26 AT 1:08 AM AEDT Shares of ICON plc rose nearly 13% on Wednesday. The clinical research company reported third-quarter earnings that beat expectations, strong new business wins and an expanded share buyback. ICON shares gained $23.22, or 12.69%, to $206.20 in early trading on the Nasdaq. The gain lifted the company's market value to about $15.9 billion. The stock is up about 10% over the past 52 weeks. Quarterly results For the third quarter, ICON reported: Revenue of $2.02 billion, down 2.9% from a year earlier Adjusted earnings of $2.66 a share, down from $3.20 a year earlier but up 3.9% from the second quarter GAAP net income of $122.1 million, or $1.58 a share, compared with a loss a year earlier Adjusted EBITDA of $336.9 million, a 16.6% margin The results beat analysts' expectations, according to market reports. The shares had jumped in premarket trading. Strong bookings Investors focused on ICON's new business. The company reported net business wins of $3.15 billion and gross bookings of $3.79 billion, up 26.9% from a year earlier. Its book-to-bill ratio, which compares new business with revenue, was 1.56. A figure above 1 means a company is adding business faster than it is completing work, which points to future revenue growth. ICON's backlog rose 4.8% from the previous quarter to $24.5 billion. Buyback expanded ICON repurchased $400 million of its shares during the quarter at an average price of $170 a share. It raised its total buyback authorization to $750 million. "We remained focused on disciplined capital allocation, returning $400 million to shareholders," Chief Executive Barry Balfe said. In August, the company issued $2.15 billion of investment-grade bonds, using the proceeds to repay debt. Updated guidance ICON updated its 2026 forecast, projecting revenue of $8.1 billion to $8.2 billion and adjusted earnings of $10.35 to $10.65 a share. "Our updated full-year financial guidance reflects sustained operational progress and higher pass-through activity," Balfe said. Pass-through revenue refers to costs ICON incurs on behalf of clients, such as payments to clinical trial sites, which it passes on to customers. Industry backdrop ICON, based in Dublin, is one of the world's largest contract research organizations. These companies run clinical trials for pharmaceutical, biotechnology and medical device companies. The industry has faced pressure over the past year as biotech funding tightened and some large drugmakers cut research budgets or reprioritized pipelines, leading to project cancellations and delays. ICON's revenue has declined as a result. The strong bookings suggest demand may be recovering. Biotech funding has improved this year, and a wave of positive clinical data across the industry, including at the European Society for Medical Oncology Congress this month, has lifted sentiment. ICON generated free cash flow of $302.4 million in the quarter. It ended September with $809 million in cash and net debt of $2.6 billion. What to watch Investors will look for evidence that the strong bookings translate into revenue growth next year, and for continued improvement in cancellation rates. They will also watch ICON's 2027 outlook, typically provided early in the new year. MEET IBT NEWS FROM BELOW CHANNELS

Icon (NASDAQ:ICLR) stock rating upgraded by UBS Group. Icon (NASDAQ:ICLR - Get Free Report) was upgraded by analysts at UBS Group to a "hold" rating in a research report issued on Wednesday, Zacks reports. ICLR has been the subject of a number of other research reports. Royal Bank Of Canada raised shares of Icon from a "sector perform" rating to an "outperform" rating and increased their target price for the company from $126.00 to $185.00 in a research report on Thursday, June 25th. Robert W. Baird set a $194.00 price objective on shares of Icon in a research note on Friday, July 31st. Truist Financial reissued a "buy" rating and set a $209.00 target price (up from $207.00) on shares of Icon in a research note on Friday, July 31st. TD Cowen boosted their target price on shares of Icon from $164.00 to $197.00 and gave the company a "buy" rating in a report on Thursday, June 25th. Finally, Citigroup cut their price target on shares of Icon from $180.00 to $175.00 and set a "neutral" rating on the stock in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Icon presently has an average rating of "Hold" and a consensus target price of $172.40. Icon trading down 4.8%. ICLR opened at $161.85 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. Icon has a fifty-two week low of $66.57 and a fifty-two week high of $203.91. The company's 50 day moving average price is $167.35 and its two-hundred day moving average price is $144.42. The firm has a market capitalization of $12.39 billion, a price-to-earnings ratio of 37.99, a PEG ratio of 7.87 and a beta of 1.24. Icon (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, topping analysts' consensus estimates of $2.55 by $0.01. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. Icon's revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.26 earnings per share. As a group, research analysts predict that Icon will post 9.56 earnings per share for the current year. Insider activity at Icon. In related news, Director Ronan Murphy sold 5,005 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $175.00, for a total transaction of $875,875.00. Following the transaction, the director directly owned 3,847 shares of the company's stock, valued at $673,225. This represents a 56.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ciaran Murray sold 2,677 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $439,804.33. Following the transaction, the director directly owned 20,452 shares in the company, valued at approximately $3,360,059.08. This represents a 11.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 22,796 shares of company stock worth $3,887,139. Corporate insiders own 44.00% of the company's stock. Hedge funds weigh in on Icon. Several institutional investors have recently made changes to their positions in ICLR. Abound Financial LLC acquired a new stake in shares of Icon in the 4th quarter valued at about $54,000. GAMMA Investing LLC raised its stake in Icon by 21.4% during the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company's stock worth $68,000 after buying an additional 69 shares during the period. Global Retirement Partners LLC boosted its holdings in Icon by 308.2% in the fourth quarter. Global Retirement Partners LLC now owns 547 shares of the medical research company's stock worth $100,000 after acquiring an additional 413 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in Icon by 120.0% in the second quarter. Parkside Financial Bank & Trust now owns 616 shares of the medical research company's stock valued at $107,000 after acquiring an additional 336 shares during the period. Finally, Blue Trust Inc. grew its stake in Icon by 207.5% in the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company's stock valued at $73,000 after acquiring an additional 444 shares during the period. Institutional investors and hedge funds own 95.61% of the company's stock. About Icon. ICON plc is a global contract research and clinical development organization headquartered in Dublin, Ireland. The company provides outsourced services to pharmaceutical, biotechnology, medical device and government organizations, supporting the development and commercialization of healthcare products. Its services span clinical trial management, clinical and regulatory consulting, data management, biostatistics, medical writing, pharmacovigilance, laboratory services, medical imaging and commercialization support. Further reading. Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.